By Ian Walker

GSK PLC raised its full-year guidance after third-quarter net profit rose, although it missed analysts' forecasts.

The British pharmaceutical giant attributed its strong performance mainly to the launch of its first respiratory syncytial virus vaccine, Arexvy, in the U.S.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

November 01, 2023 03:35 ET (07:35 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more GSK Charts.